Correspondence
In Brief Maffioletti et al. generate human 3D artificial skeletal muscles from healthy donors and patient-specific pluripotent stem cells. These human artificial muscles accurately model severe genetic muscle diseases. They can be engineered to include other cell types present in skeletal muscle, such as vascular cells and motor neurons.
INTRODUCTION
Skeletal muscle is the most abundant human tissue, and it is responsible for movement, posture, temperature control, and various metabolic functions. It is composed of aligned multinucleated myofibers, and its repair and regeneration rely on resident stem or progenitor cells, of which satellite cells are the best characterized (Tedesco et al., 2010) . Nonetheless, impaired muscle regeneration occurs in acute or chronic conditions, such as significant trauma (Grogan et al., 2011) , or incurable inherited disorders, such as muscular dystrophies (Mercuri and Muntoni, 2013) . Artificial human skeletal muscles would provide an invaluable tool to study pathological mechanisms, test potential therapeutics, and develop tissue replacement protocols. Use of a similar approach in other tissues has proved transformational for drug development and regenerative medicine by means of organoid technology (Fatehullah et al., 2016; Lancaster and Knoblich, 2014) .
Although several studies have reported methods to engineer rodent skeletal muscle tissue (Carosio et al., 2013; Corona et al., 2014; Huang et al., 2005; Juhas et al., 2014; Machingal et al., 2011; Shandalov et al., 2014; VanDusen et al., 2014) , fewer groups have used human cells (Chiron et al., 2012; Fuoco et al., 2015; Madden et al., 2015; Powell et al., 1999; Quarta et al., 2017; Tchao et al., 2013) . Apart from a recent study on healthy donor human pluripotent stem cells (hPSCs) for muscle tissue engineering (Rao et al., 2018) , most studies used primary human cells from invasive muscle biopsies, facing hurdles such as poor cell availability, limited cell expansion potential, and exhaustion of differentiation ability. In addition, although there is an increasing need to develop clinically relevant multilineage patient-specific models (Giacomelli et al., 2017) , no such isogenic human skeletal muscle model has been derived to date. These obstacles hinder the translational potential of these platforms for muscle diseases.
To overcome these limitations, here we have exploited the virtually unlimited proliferative capacity and controllable differentiation of human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) (referred to collectively as hPSCs) (Inoue et al., 2014) to produce 3D artificial skeletal muscle constructs for complex muscle disease modeling. hPSCs were induced to skeletal myogenesis within a biocompatible hydrogel using established protocols (Caron et al., 2016; Maffioletti et al., 2015; Tedesco et al., 2012) . Artificial muscles could be made using hiPSCs from Duchenne, limb-girdle type 2D, and LAMIN A/C (LMNA)-related muscular dystrophies. Our 3D platform modeled cellular hallmarks of LMNA-related muscular dystrophies with high fidelity. Finally, essential cell types present in muscle tissue, such as vascular cells and motor neurons, were derived from the same hiPSC source to generate isogenic multilineage muscle constructs.
RESULTS

3D Artificial Muscles Can Be Generated from Multiple Healthy and Dystrophic hPSC Lines
To generate 3D human artificial skeletal muscles, hPSC-derived myogenic cells (healthy and dystrophic) ( Figure 1A ) were embedded in fibrin hydrogels and differentiated, adapting a cardiac tissue engineering platform (Hansen et al., 2010) . Fibrin was polymerized from fibrinogen in molds between two flexible silicone posts providing continuous tension to the gel, sufficient to direct orientation of cells along the force axis ( Figure 1B ). Over 10 days, cells remodeled the matrix, generating a 7-8 mm long strip of tissue containing structures resembling skeletal myofibers ( Figures 1C, 1D , and S1A). Both transgene-based (Maffioletti et al., 2015) and transgene-free (Caron et al., 2016) differentiation protocols produced muscle constructs (Figures 2A and S1B) . Transgene-based muscle constructs were generally used due to the better alignment of myofibers, easier scalability of cultures, and experimental cost-effectiveness.
Immunolabeling of artificial muscles from hESCs and hiPSCs-healthy donor, Duchenne muscular dystrophy (DMD), limb-girdle muscular dystrophy type 2D (LGMD2D) ( Figure S1C ), and LMNA-related muscular dystrophies-showed homogeneous presence of myosin heavy chain (MyHC) + multinucleated myotubes oriented along the force axis of the hydrogels (Figures 2A and 2B) , as observed with primary human myoblasts within the same platform ( Figure S1D ). Transverse sections of artificial muscles revealed abundant MyHC + muscle fibers surrounded by LAMININ + extracellular matrix ( Figure 2C ). Western blot analysis confirmed production of MyHC protein ( Figure 2D ). Healthy and dystrophic muscle constructs also expressed markers of skeletal muscle determination and maturation (e.g., MYOD and DYSTROPHIN) ( Figure 2E ). Immunohistochemical staining highlighted proteins associated with skeletal muscle maturation, such as sarcomeric actin ( Figure 2F ). Electron microscopy revealed that muscle constructs displayed some degree of cytoskeletal organization into sarcomeres, the basic functional unit of striated myofibers ( Figure 2G ). Functional myotubes within the artificial muscles were detected by caffeine-induced calcium transients ( Figure S1E ).
Pax7 marks a population of self-renewing myogenic stem cells known as satellite cells (Tedesco et al., 2010) . To assess whether our 3D platform generated and provided a niche for Pax7 + cells, we induced myogenic commitment and differentiation of transgene-free hiPSC-derived myogenic progenitors directly in hydrogels. This resulted in PAX7 + cells juxtaposed to myofibers, albeit with variability among the tested hiPSC lines ( Figure 2H ). To further characterize hPSC-derived artificial muscles, they were implanted into immunodeficient mice. Tibialis anterior (legend continued on next page) (TA) muscles of non-obese diabetic (NOD)-severe combined immunodeficiency (SCID)-gamma mice (NSG) (N = 24) were injured, and a strip of host tissue was replaced with GFP-expressing hPSC-derived artificial muscles. GFP + implants were identifiable in explanted TA muscles at various time points ( Figures 2I and S2A S2C , and S2D). Engraftment was confirmed by expression of human musclespecific transcripts in implanted muscles, and blood vessels within the implants were detected by immunolabeling for CD31 ( Figures S2E-S2G ). We further investigated vascularization of the artificial muscle by systemically injecting fluorescent isolectin into the mouse circulation before harvesting implanted muscles. Isolectin + vessels were evident within the implant, confirming functional vascularization ( Figure 2K ).
Therefore, fibrin hydrogels under uniaxial tension stimulate efficient and aligned 3D skeletal myogenic differentiation of healthy and dystrophic hPSCs. Muscle constructs recapitulate distinctive molecular, structural, and functional features of skeletal muscle and engraft in immunodeficient mice.
hiPSC-Derived Artificial Skeletal Muscles Enable Disease Modeling of Skeletal Muscle Laminopathies
Organoids have great potential for disease modeling and drug development, so we examined whether our organoid-like, artificial skeletal muscle could model severe and incurable forms of muscular dystrophy. We also hypothesized that the 3D nature of our hydrogels would facilitate detection of pathological hallmarks less evident in standard bi-dimensional cultures. To investigate this, we examined artificial muscles generated from hiPSC derived from patients with muscular dystrophies caused by mutations in the LMNA gene. LMNA mainly encodes the A-type lamins, lamin A and lamin C (LAMIN A/C), nuclear envelope proteins that assemble with B-type lamins into the nuclear lamina, providing structural support and regulating gene expression (Worman, 2012) . LMNA mutations cause a plethora of diseases called laminopathies, of which three forms affect skeletal muscle (Maggi et al., 2016) : limb-girdle muscular dystrophy type 1B (LGMD1B), autosomal dominant Emery-Dreifuss muscular dystrophy 2 (EDMD2), and LMNA-related congenital muscular dystrophy (L-CMD). Abnormalities in nuclear morphology are a key histological feature of skeletal muscle laminopathies (Park et al., 2009) , and using hiPSC-based modeling could provide a unique, non-invasive tool to address open questions, such as challenging genotype-phenotype correlations, and develop new therapeutics (Scharner et al., 2015) .
3D artificial muscles were made by differentiating three LMNA mutant hiPSCs from patients with skeletal muscle laminopathies, referred to by their mutation as LMNA L35P, R249W, and K32del ( Figures 1A, 2A , and 3A). 3D nuclear reconstruction of mutant LMNA cells differentiated in artificial muscles highlighted features less prominent in standard monolayer cultures ( Figure 3B ). This prompted us to quantify nuclear abnormalities, including elongation, deformities, and presence of blebs (Figure 3C) , in LMNA mutant hiPSC-derived artificial muscles. For controls, we used wild-type (WT) hPSCs and LGMD2D hiPSCs ( Figures 1A and 2A) , which have not been reported to have dysmorphic nuclei (Kirschner and Lochm€ uller, 2011) . As expected, nuclei in artificial muscle derived from control cells did not display significant nuclear abnormalities. In contrast, all mutant LMNA artificial muscles showed a significant proportion of cells with nuclear aberrations (p = 0.0022, N = 6) ( Figure 3C ; Table S1 ; Videos S1 and S2).
Nuclear elongation was a predominant abnormality, in line with biopsy-derived primary myoblast 3D cultures (Bertrand et al., 2014) . Measurements confirmed that laminopathic muscle constructs contained significantly elongated nuclei compared to control artificial muscles (p = 0.0022) ( Figures 3D and 3E ), supporting using this outcome measure in future therapy screening platforms. Thus, hiPSC-derived artificial muscles recapitulate cellular hallmarks of skeletal muscle laminopathies with high fidelity and are amenable to model severe muscle disorders.
Increasing Histological Complexity: Multilineage hiPSC-Derived 3D Artificial Skeletal Muscles Skeletal muscle tissue also contains non-muscle support cell types, such as vascular endothelial cells (ECs) and pericytes (PCs), which permit blood perfusion while controlling homeostasis of the muscle stem cell compartment (Christov et al., 2007) . Therefore, adding ECs and PCs to artificial muscles could generate a more physiologically relevant model in vitro and improve survival of larger constructs in vivo, which require prompt vascularization to prevent hypoxia-induced cell death (Criswell et al., 2013; Gholobova et al., 2015; Koffler et al., 2011; Levenberg et al., 2005) . To achieve these aims, we first derived isogenic ECs and PCs from the same hiPSCs used for myogenic differentiation ( Figure S3A ) (Orlova et al., 2014) . We then combined isogenic hiPSC-derived ECs, PCs, and myogenic (B) Comparison of confocal 3D nuclear reconstructions of the same iPSC lines shown in (A) differentiated as monolayer cultures (left) versus 3D artificial muscle constructs (right). Nuclei are immunolabeled for LAMIN A/C. (C) Box and whiskers graph quantifying nuclear abnormalities in hiPSC-derived artificial muscle generated from 3 patients affected by LMNA-related muscular dystrophies (red color shades) versus 3 control donors (blue color shades).
LGMD2D artificial muscles are included as negative control, because they do not have nuclear abnormalities. Lower panel: representative images of 3D-reconstructed nuclei used to score laminopathy versus control muscles in the graph. **p = 0.0022, Mann-Whitney U test. n = 6 in CTRL group and 6 in LMNA mutant group (3 cell populations per group in 2 independent experiments). A minimum of 45 nuclei/hydrogel/experiment across 8 random high-power fields were scored. Boxes, 25 th to 75 th percentiles; horizontal line inside, median; +, mean; whiskers, min to max values. (D) Scatter dot plot of the specific length of the nuclei scored in (C). **p = 0.0022, Mann-Whitney U test. n = 6 in CTRL group and 6 in LMNA mutant group (3 cell populations per group in 2 independent experiments). Each symbol is one nucleus. Error bars: mean ± SD.
(E) Distribution plot of the graph in (D). Scale bars: (A and B) 15 mm; (C) 10 mm. For additional information, see Table S1 and Videos S1 and S2. (legend continued on next page) cells within hydrogels under tension and tested media that supported growth and differentiation of those lineages. After 10 days in culture, long (up to 0.9 mm) CD31 + vessel-like formations coexisted in the same 3D environment close to isogenic myofibers ( Figure 4A ). The 3D nature of EC networks was visualized through hyper-stack images processed with depth color-coding for CD31 immunolabeling ( Figure 4B ). Due to the absence of unequivocal PC-specific markers (Armulik et al., 2011), hiPSCderived PCs were transduced with a lentivirus encoding for GFP to allow their detection within artificial muscles. Immunofluorescence demonstrated alignment and coexistence of myofibers, ECs, and PCs within the same 3D environment ( Figures  4C-4E ). In vivo studies of muscle function in immunodeficient mice suggested enhanced force recovery only in muscles receiving multicellular versus single-lineage (i.e., only myofibers) artificial muscle implants ( Figure S3B ). Another key cell type for skeletal muscle is the spinal motor neuron. Deriving primary human motor neurons is challenging; however, several protocols are available to differentiate them from hPSCs (Patani, 2016) , including their coculture with primary myotubes (Steinbeck et al., 2016) . Therefore, developing an isogenic human muscle-motor neurons platform would model neuromuscular disorders in a personalized fashion. To this aim, we differentiated hiPSCs into neural progenitors (Stacpoole et al., 2011) and further adapted our tri-lineage culture system to enable differentiation of neural precursors into motor neurons. We obtained stable 3D artificial muscle constructs containing four distinct isogenic cell types, i.e., myofibers, ECs, PCs, and SMI32+ cells with long axon-like processes resembling motor neurons spreading from hiPSC-derived neurospheres placed above the hydrogels (Figures 4F and 4G) .
We next investigated generation of neuromuscular junctions through muscle-motor neuron bi-lineage models. Interactions between the two cell types were optimized by employing a differentiation paradigm that generates a highly enriched motor neuron population ( Figure S3C ) (Hall et al., 2017) and allows seeding of single-cell neural precursors within the hydrogel. DMD muscle constructs were made containing WT motor neurons, which showed alpha-bungarotoxin + acetylcholine receptors and striated myofibers with the sarcomeric protein Titin (Figures 4H and 4I) , indicating a positive effect on myofibers' maturation exerted by motor neurons. Thus, we generated complex, 3D, multilineage, artificial skeletal muscle models from hiPSCs.
DISCUSSION
Use of hPSCs for tissue engineering and complex disease modeling is expanding, and exciting results have been obtained with hiPSC-derived organoids (Passier et al., 2016) . Here we show that 3D constructs resembling skeletal muscle tissue can be generated by differentiating healthy donor and disease-specific hPSCs within fibrin hydrogels under unidirectional tension. We have generated artificial muscles from patients affected by severe forms of muscle diseases with different genetic inheritance, namely, Duchenne (X-linked), LGMD2D (autosomal recessive), and LMNA-related (autosomal dominant) muscular dystrophies. Our hiPSC-derived 3D platform recapitulated nuclear abnormalities characteristic of LMNA-related muscular dystrophies. Nuclear elongation was the most prominent abnormality, consistent with reports using LMNA mutant mice and primary human myoblasts (Bertrand et al., 2014; Nikolova et al., 2004) , supporting the high fidelity of our 3D platform for modeling skeletal muscle laminopathies. We also provide proof of principle of hPSC-derived artificial muscle engraftment, laying the foundation for in vivo modeling and drug testing in humanized dystrophic muscles. A major advantage of using hPSCs for muscle bioengineering is the ability to derive different cell types from the same cellular source, and here we provide evidence of generation of isogenic, multilineage, hPSC-derived artificial skeletal muscles. Although our data and published work (Rao et al., 2018) indicate that skeletal muscle properties can be observed in bundles of hPSCderived myofibers, our results further indicate that maturation of fully functional artificial muscles might require contribution from other cellular lineages, such as vascular cells and motor neurons (Christov et al., 2007; Ecob-Prince et al., 1986; Kostallari et al., 2015; Martin et al., 2015) . This could be particularly relevant for in vitro studies of non-muscle-specific defects in muscle disorders (Dabiré et al., 2012; Palladino et al., 2013) or to predict off-target effects of skeletal muscle-directed therapeutics. Artificial muscles containing vascular cells will likely improve engraftment upon implantation in vivo, via rapid anastomosis with the host circulation, in line with improved engraftment of vascularized muscle constructs derived from primary myoblasts (Perry et al., 2017; Quarta et al., 2017) . Moreover, multilineage artificial muscles could also provide insights into human muscle regeneration dynamics, because we observed generation of GFP + myofibers in constructs in which only PCs had been transduced with a GFP-encoding lentiviral vector ( Figure 4D ). This suggests myogenic potential of PCs or their recruitment from differentiating muscle, similar to that described in mice with lineage tracing experiments (Dellavalle et al., 2011) . This platform can be further engineered to include other pluripotent derivatives, such as different muscle interstitial cells (Tedesco et al., 2017) . Nonetheless, bioengineering an all-hPSCderived muscle will require highly specialized culture conditions, potentially with a combination of transgene-based (e.g., Darabi et al., 2012; Tedesco et al., 2012) and transgene-free (e.g., Caron et al., 2016; Chal et al., 2015) differentiation methods, because culture conditions to maintain non-myogenic cells might interfere with transgene-free, small molecule-based myogenic differentiation of hPSCs. Further optimization of artificial muscles includes improvement of maturation via chemical, electrical or optical stimulation and scaling down for high-throughput screening. Moreover, culture in autologous fibrinogen (de la Puente and Ludeñ a, 2014) would enable a highly personalized platform. Finally, human muscle models would reduce laboratory animal use for toxicity testing. In conclusion, this hPSC-derived artificial skeletal muscle platform could bring together regenerative medicine and drug development under the same translational technology, advancing knowledge on the pathogenesis and development of therapies for muscle diseases.
EXPERIMENTAL PROCEDURES
Generation of 3D Skeletal Muscle Constructs 15 hPSC lines (1 hESC line + 14 hiPSC lines) and 1 primary human myoblast line were used. Hydrogels were produced as published (Hansen et al., 2010) and according to the manufacturer's instructions (EHT Technologies, Hamburg). 10 6 myogenic cells pre-treated with ROCK inhibitor (10 mM; 1-2 hr) were used per construct (total volume: 120 mL). Artificial muscles were cultured at 37 C with 5% CO 2 supplementing the medium with 33 mg/mL aprotinin (Sigma, A3428) to prevent fibrinogen degradation. To induce myogenic differentiation, 1 mM 4-OH tamoxifen was added 48 hr after polymerization in proliferation medium and then 24 hr later in differentiation medium. For transgene-free myogenic differentiation (Genea Biocells), progenitors were cultured for 7 days in commitment medium before cells were combined with fibrin, switching to differentiation medium 2 days later. To generate PAX7 + cells, myogenic commitment was induced for 2 days in standard monolayer culture conditions and then continued in 3D for 5 days before switching to differentiation medium; hydrogels were cultured for a total of 14 days. Pax7 + cells were observed in 1 of 3 lines (NCRM1 iPSCs). Triple-lineage constructs were made with the same method using a mix of 70% myogenic cells (7 3 10 5 ) and 30% vascular cells (6 3 10 4 ECs and 2.4 3 10 5 PCs). Muscles were cultured in a 1:1 mix of human iPSC-derived mesoangioblast-like inducible myogenic cells (HIDEM) proliferation medium (Maffioletti et al., 2015) and endothelial medium A (EC-SFM [endothelial cell-serum-free basal medium]; 1% platelet-poor, plasma-derived serum; 30 ng/mL vascular endothelial growth factor [VEGF] ; 20 ng/mL basic fibroblast growth factor [bFGF]) for 48 hr and then in a 1:1 mix of HIDEM differentiation medium (Maffioletti et al., 2015) and endothelial medium B (Lonza, CC-3162) after the second tamoxifen administration. Muscles were cultured for 10 days at 37 C with 5% CO 2 , changing the medium every other day. Human fibrinogen was kindly provided by Prof. H. Redl (LBG, Vienna). Constructs containing four lineages (muscle + ECs + PCs + motor neurons) were made as described earlier; after 1 hr of polymerization, 6 neurospheres (neural progenitor cells [NPCs] ) were decanted on top of the hydrogels using 10 mL of fibrin. After the second hour of polymerization, hydrogels were placed in media containing an equal ratio of Iscove's Modified Dulbecco's Medium (IMDM)-based HIDEM proliferation medium, EC-SFM (Orlova et al., 2014) , and a chemically defined medium (Stacpoole et al., 2011) , supplemented with heparin (5 mg/mL) and retinoic acid (0.1 mM). NPC differentiation to motor neurons was achieved through supplementation of the media with retinoic acid for 7 days and then with retinoic acid and purmorphamine (1 mM) until fixation at day 14.
To produce hydrogels containing myofibers (70%) and single-cell motor neurons (30%) (derived as per Hall et al., 2017) , constructs were cultured for 48 hr using a 1:1 mix of HIDEM proliferation medium with 1% fetal bovine serum (FBS) and neural precursor medium (Shi et al., 2012) . The same mix was supplemented with 4-OH tamoxifen and 0.1 mM g-secretase inhibitor (Sigma, L1790) to induce myogenic and neural differentiation. After 24 hr, medium was changed to administer the second tamoxifen pulse. Hydrogels were kept in culture for 15 days at 37 C with 5% CO 2 , changing the medium mix with 0.1 mM g-secretase inhibitor every day. At day 5, the medium was supplemented with agrin (R&D Systems, 550-AG/CF) to promote neuromuscular junction formation. Agrin concentrations of 0.1, 0.5, and 1 nM were used over the 3 initial days, and the final concentration was kept until fixation of constructs. Additional information can be found in Supplemental Experimental Procedures. , and goat anti-Emerin (1:50) (Santa Cruz, sc8086) antibodies overnight at 4 C in TBS, 1% BSA, and 0.5% Triton X-100. The next day, hydrogels were washed with TBS 6 times hourly and incubated overnight with Hoechst 33342 (Sigma, B2261) plus species-specific secondary antibodies (Alexa Fluor 488, 546, and 647) (Thermo Fisher Scientific). The following day, hydrogels were washed 6 times with TBS and embedded in mounting medium (Dako, S3023A) on glass slides. A confocal microscope (Leica, SPE2) was used for imaging, using 953 magnification to take 5 to 9 z stacks (step size: 0.5 mm) of randomly selected regions (final thickness: 12-82 mm).
The z stacks were 3D reconstructed and analyzed based on LAMIN A/C immunolabeling using Imaris 8.4.1 software (Bitplane). Nuclei were analyzed by scoring the number of abnormalities per field and by measuring major axis length. Oval or slightly elongated nuclei were scored as normal. Three LMNA mutant patients and three controls were quantified. A minimum of 45 nuclei per hydrogel per experiment across 8 random fields was scored. Reproducibility was validated by 3 independent operators (one researcher was blinded) (Table S1 ). Normal distribution of nuclear abnormalities was tested using the D'Agostino and Pearson test and statistical testing compared the LMNA mutant group (N = 6; 3 cell populations in 2 experiments) versus the non-mutant group (N = 6; 3 cell populations, 2 experiments) using Mann-Whitney U test, because one cell population per group did not have a normal distribution of values. 
Ethics
Statistics
Values are mean ± SD or SEM (as specified). Specific N or n values and statistical tests are indicated in figure legends. Data were analyzed with Microsoft Excel and GraphPad Prism.
DATA AND SOFTWARE AVAILABILITY
The raw data reported in this paper have been deposited in Mendeley Data and are available at https://doi.org/10.17632/d826fxhr3b.1. (8) 0% (0) 
SUPPLEMENTAL INFORMATION
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Cell cultures and differentiation protocols
15 distinct hPSC lines (1 hESC + 15 hiPSC lines) and 1 primary human myoblast line were utilized in this study. Both transgene-based and transgene-free skeletal myogenic differentiation protocols of hPSCs were utilized in this work. hPSC-derived inducible myogenic cells (transgene-based; also known as HIDEMs/HEDEMs) were derived and maintained in culture as previously described (Maffioletti et al., 2015; Tedesco et al., 2012) . Shef-6 cells (hpscreg.eu/cell-line/UOSe006-A) were used for hESC experiments and were kindly provided by Prof. P. Andrews (University of were kindly provided by Prof. M. Oshimura (Tottori University, Japan); 2) LGMD2D iPSC were generated from somatic cells provided by the Munich Tissue Culture Collection (MTCC; Friedrich-Baur Institute, Munich, Germany), were previously described (Tedesco et al., 2012) and are also deposited in hpscreg.eu (UCLi005-A);
3) Three distinct LMNA-mutant iPSC lines were reprogrammed and provided by Cellular Dynamics International Inc. and CureCMD. Inducible myogenic cells were differentiated in DMEM, 2 % horse serum, 2 mM glutamine, 100 IU + 0.1 mg / ml penicillin/streptomycin (i.e. differentiation medium) on Matrigel-coated dishes; 1 μM 4-OH tamoxifen (Sigma, H7904) was added twice to the medium, once in proliferation medium when cells reached 90%-100% confluence and the following day in differentiation medium as previously described (Maffioletti et al., 2015; Tedesco et al., 2012) . For transgene-free myogenic differentiation, 3 healthy hiPSC lines (NCRM1, NCRM5 and A13777, details above) were differentiated using a published and commercially available small molecule-based protocol (Caron et al.,
2016)(Genea Biocells, Skeletal Muscle Differentiation Kit, manufacturer's instructions were followed with minor adaptations). Primary human skeletal myoblasts were purchased from ThermoFisher (GIBCO® Human Skeletal Myoblasts, cat. no.
A12555; grown and differentiated following manufacturer's instructions).
Endothelial cells and pericytes were derived from SBI iPSCs by adapting a previously published protocol (Orlova et al., 2014) . Specifically, Gentle Cell Dissociation Reagent was used to create small hiPSC aggregates (STEMCELL Technologies, 07174), which were plated on Matrigel (according to (Orlova et al., 2014) ) or Vitronectin (Stemcell Technologies, 07180). Cells were FACS-sorted into CD31 + and CD31 -fractions, obtaining comparable results to the Dynabead-based method described in the original paper. Endothelial cells were cultured as previously published (Orlova et al., 2014) , whereas pericytes were cultured as described in Orlova et al. for the initial passages and then adapted to a previously described MegaCell (Sigma)-based medium optimized for skeletal muscle pericytes (Maffioletti et al., 2015; Tedesco et al., 2012) to improve expansion. and Thermo Fisher A18945 hiPSCs where then used in 3D co-culture experiments.
Generation of 3D artificial muscle constructs (extended version)
Fibrin gels were produced as previously published (Hansen et al., 2010) using 3.5 mg/ml human fibrinogen (TISSUCOL DUO 500, Baxter) and 10% Matrigel (BD, 356230) polymerized by adding 3 U/ml thrombin (Biopur, 10-13-1104) to the solution.
The silicone posts used for gel polymerization are commercially available (EHT Technologies, GmbH Hamburg). 1 x 10 6 cells were used for each artificial muscle (total volume 120μl). Artificial muscles were kept in culture at 37°C with 5% CO2 supplementing the medium with 33 μg / μl aprotinin (Sigma, A3428) to prevent fibrinogen degradation. To induce myogenic differentiation, 1 μM 4-OH tamoxifen was added 48 hours after polymerization in proliferation medium and then 24 hours later in differentiation medium. Multi-lineage artificial muscles were generated with the same method using a cell mix composed of 70% myogenic cells ( 
DNA extraction and sequencing
QIAamp DNA Mini Kit (Qiagen, 51304) was used to extract DNA from cell pellets following manufacturer's instructions. Sequencing was performed by Source BioScience (Nottingham, UK) using the following primers:
GAATCCCCTCTCCTCGCTTC (F) and GATCTTCTGGGGTGGCAGAG (R).
RNA extraction and expression analyses (RT-PCR and qRT-PCR)
RNA was extracted from cell pellets using the RNeasy Mini kit (Qiagen, 74104) following manufacturer's instructions. Trizol reagent (Life technologies, 15596-026) was used to extract RNA from artificial muscles after homogenization as detailed in the manufacturer's protocol. RNA yield and purity was assessed with a Nanodrop; variable amounts of RNA (between 500 ng and 1 μg) were then retro-trascribed to cDNA with the ImProm-II™ Reverse Transcription System kit (Promega, A3800 hiPSCs, whose error bars in Figure 2E represent intra-experimental replicates (n = 3). Ct data were normalized using GADPH gene expression values for each sample analyzed using the ΔΔCt method (Schmittgen and Livak, 2008) 
Western blot
Proteins were extracted with cold lysis buffer (50 mM Tris HCL pH 7.4, 1 % Triton X-100, 1 mM EDTA pH 8, 150 mM NaCl in ddH2O) with 1 mM PMSF (Thermo Scientific, 36978) and a protease inhibitor cocktail (Roche, 04693159001). Samples were homogenized on ice. Samples were incubated on ice for 30 minutes and centrifuged at 10000 rpm for 10 minutes at 4°C. Sample concentration was determined using a colorimetric reaction (BioRad, 500-0113). 30μg of proteins per sample were loaded in reducing loading buffer (Alpha Aesar, J61337) on a precast gel (4-15%; Biorad, 345-0028) and run at 100 V. Proteins were transferred onto a PVDF membrane, which was then blocked with 5% non-fat dry milk (Cell Signaling, 
Electron microscopy
Samples were washed twice in PBS and incubated for 10 minutes at 37 °C in 30 nM 2,3-butanedione monoxime (Sigma, cat. no. B0753). Samples were then fixed O/N at 4 °C in 0.36 % glutaraldehyde (Sigma, cat. no. G7526). Post-fixation was performed with 1 % osmium tetroxide (Science Services, cat. no. E19110) for 2 hours. Samples were then dehydrated, embedded into a glycid ether-based resin and processed in 50 nm-thick sections. Images were acquired on a Zeiss LEO 912AB microscope.
Imaging and analysis of calcium transients
Calcium transients were measured after loading hiPSC-derived artificial muscle Figure   S1H . The graph shows ΔF/F traces, which is the measured fluorescence relative to the average resting fluorescence of each point, before the administration of caffeine.
Image analysis was conducted with ImageJ and Microsoft Excel was used to generate the graphs.
In vivo implantation studies
Adult NOD-scid-gamma immunodeficient mice (NSG) were used for transplantation assays (N = 24). Animals were anesthetized with isoflurane (in O2 at 2 liters / minute) and the surgery was performed under sterile aseptic technique. Briefly, a longitudinal incision was performed on the skin on top of the tibialis anterior (TA) muscle to expose the muscle tissue. A 2 mm deep, 8 mm longitudinal incision was then performed to open an intramuscular pocket and a volume of muscle tissue corresponding to the hydrogel(s) needing implantation removed. Occasional bleeding was controlled with a high temperature cauterizer (Bovie Medical, AA01). Before implantation, gels were washed twice with sterile PBS and then implanted into the muscle pocket. 8μL of fibrin glue (TISSUCOL DUO 500, Baxter) was added on top of the pocket containing the implant to seal the wound and keep the artificial tissue in place. 1 or 2 gels were implanted respectively for short (1 week) or long time (2-4 weeks) analyses. The skin was sutured with 4.0 Vicryl sutures (Ethicon) and the mouse was allowed a gradual recovery from anaesthesia. Analgesia (Carprofen) was administered 40 minutes before surgery and the day after to minimize discomfort.
The surgeon was not aware of the genotype or composition of the implants. All mice recovered promptly without post-operative adverse events.
For functional vascularization assays, DyLight® 594 GSL I-B4 isolectin (Vector Laboratories, DL-1207) was injected into the tail vein of NSG mice 1 week after surgical procedure (100 μg/injection). Animals were humanely killed 20 minutes after injection, muscles dissected and then cryopreserved for further analyses. Isolectin staining was imaged on muscle sections with a fluorescent microscope (excitation wavelength: 592 nm).
Mouse muscle tissue processing
Tissues were harvested from the animals at different time points and cryopreserved as previously described (Gerli et al., 2014) . Muscles were sectioned (thickness: 8 μm) using a cryostat (Leica, CM1850) and collected on polarized glass slides.
Samples for RNA extraction were collected during muscle sectioning. Sections were stored at -80°C.
In vivo force assessment
Four weeks after surgery (performed as described in the "In vivo implantation studies section" above), muscle function was assessed for the right and left tibialis anterior (TA) muscles. Two hydrogels per NSG tibialis anterior muscle were implanted and chimeric muscles were assessed one month after implant. A total of 17 mice and 34 muscles were assessed (N = 6 muscles containing myofibres-only hiPSC-derived hydrogels, 6 muscles containing multicellular hiPSC-derived hydrogels, 5 injury-only muscles and 34 uninjured contralateral muscles). One injury-only mouse was excluded from the analysis because of technical problems during recording of muscle force. The operating surgeon was blind to the type of implanted hydrogel and muscle physiologists were blind to all groups. The muscle function assessment procedure was adapted from standard protocols (Liu M et al., 2005; Sharp PS et al., 2005 ) and has been previously described (Foster H et al., 2008) . Mice were deeply anesthetized with Hypnorm (VetPharma, Leeds, UK) and Hypnovel (Roche, Welwyn
Garden City, UK) as previously described and were carefully monitored throughout the experiment to ensure that there was no reflex response to toe pinch. The distal tendon of the TA muscle was dissected from surrounding tissue and tied with 4.0 braided surgical silk (Interfocus, Cambridge, UK). The sciatic nerve was exposed and superfluous branches axotomized, leaving the TA motor innervation via the common peroneal nerve intact. The mouse was placed on a thermopad (Harvard Apparatus, Edenbridge, UK) to maintain body temperature at 37 °C. The foot was secured to a platform and the ankle and knee immobilized using stainless steel pins. The TA tendon was attached to the lever arm of a 305B dual-mode servomotor transducer (Aurora Scientific, Aurora, Ontario, Canada) via a custom-made steel s-hook. TA muscle contractions were elicited by stimulating the proximal part of common peroneal nerve via bipolar platinum electrodes, using supramaximal square-wave pulses of 0.02 ms (701A stimulator; Aurora Scientific). Data acquisition and control of the servomotors were conducted using a Lab-View-based DMC program (Dynamic muscle control and Data Acquisition; Aurora Scientific). Optimal muscle length (Lo) was determined by incrementally stretching the muscle using a micromanipulator until the maximum isometric twitch force was achieved. Maximum isometric tetanic force (Po) was determined from the plateau of the force-frequency relationship following a series of stimulations at 10, 30, 40, 50, 80, 100, 120, and 150 Hz. A 1-minute rest period was allowed between each tetanic contraction. For direct muscle stimulation two custom made electrodes were inserted in the mid belly of the muscle and the whole procedure was repeated using 4V stimulation. Muscle length was measured using digital calipers based on well-defined anatomical landmarks near the knee and the ankle. Results presented are the ratio of maximum tetanic force of the treated vs the untreated contralateral limb for direct muscle stimulation only, as the injury model and specific timeline appeared not to give sufficient time for innervation and assessment via sciatic nerve stimulation.
